# Rubinstein–Taybi Syndrome: A Comprehensive Analysis of a Polish Cohort with Most Cases Due to Novel CREBBP and EP300 Variants

**Authors:** Agata Cieślikowska, Agnieszka Madej-Pilarczyk, Piotr Iwanowski, Katarzyna Iwanicka-Pronicka, Dorota Wicher, Maria Jędrzejowska, Dorota Jurkiewicz, Marzena Gawlik, Dorota Piekutowska-Abramczuk, Paulina Halat-Wolska, Jagoda Błaszkiewicz, Izabela Mendrek, Krystyna Chrzanowska, Marlena Młynek, Piotr Stawiński, Joanna Kosińska, Małgorzata Krajewska-Walasek, Elżbieta Ciara

PMC · DOI: 10.3390/genes16101206 · Genes · 2025-10-14

## TL;DR

This study analyzed 17 Polish patients with Rubinstein–Taybi Syndrome and found that most had novel genetic mutations in CREBBP or EP300, highlighting genetic diversity in this population.

## Contribution

The study reports a high proportion of novel and gross deletion variants in a Polish cohort of Rubinstein–Taybi Syndrome patients.

## Key findings

- 13 out of 17 patients had novel pathogenic variants in CREBBP or EP300.
- 12% of all variants were gross deletions, with 15% in CREBBP.
- The findings suggest possible population-specific genetic differences in Rubinstein–Taybi Syndrome.

## Abstract

Background: Rubinstein–Taybi syndrome (RSTS) is characterized by intellectual disability, short stature, distinctive facial dysmorphism, broad thumbs/halluces, hearing loss, congenital heart or renal defects, and cryptorchidism in males. Pathogenic variants in CREBBP (~90% of cases) or EP300 (~10%) underlie the disorder, with ~88% single nucleotide variants (SNVs) and ~12% copy number variants (CNVs) in CREBBP. Materials and Methods: We investigated 17 patients clinically diagnosed with RSTS at a tertiary hospital in Poland. Genetic confirmation was achieved by next-generation sequencing, multiplex ligation-dependent probe amplification (MLPA), array comparative genomic hybridization (aCGH), or Sanger sequencing. Results: Pathogenic variants were identified in CREBBP (13/17, 76%) and EP300 (4/17, 24%). Variant types included frameshift indels (6/17, 35%), missense (4/17, 24%), nonsense (3/17, 18%), splice-site (2/17, 12%), and gross deletions (2/17, 12%). Notably, 13/17 (76%) were novel: ten in CREBBP (c.−49_12del, c.289C>T, c.1093_1096del, c.1094A>G, c.3178A>T, c.3401A>T, c.(3836+1_3837−1)_(4394+1_4395−1)del, c.4133+2T>G, c.4963dup, c.5028_5029dup) and three in EP300 (c.1942C>T, c.3044_3045del, c.4713_4722del). Among the novel CREBBP variants, eight occurred de novo and two had unknown inheritance. Two novel EP300 variants occurred de novo and one was of unknown origin. Conclusions: This first Polish RSTS cohort demonstrates a considerable proportion of gross deletions (12% overall; 15% in CREBBP) and an unexpectedly high rate of novel variants (76%), suggesting possible population-specific differences. These findings underscore the genetic heterogeneity of RSTS and highlight the importance of comprehensive molecular diagnostics and studies in underrepresented populations.

## Linked entities

- **Genes:** CREBBP (CREB binding lysine acetyltransferase) [NCBI Gene 1387], EP300 (EP300 lysine acetyltransferase) [NCBI Gene 2033]
- **Diseases:** Rubinstein–Taybi Syndrome (MONDO:0019188)

## Full-text entities

- **Genes:** EP300 (EP300 lysine acetyltransferase) [NCBI Gene 2033] {aka KAT3B, MKHK2, RSTS2, p300}, CREBBP (CREB binding lysine acetyltransferase) [NCBI Gene 1387] {aka CBP, KAT3A, MKHK1, RSTS, RSTS1}
- **Diseases:** hearing loss (MESH:D034381), facial dysmorphism (MESH:C565579), cryptorchidism (MESH:D003456), short stature (MESH:D006130), intellectual disability (MESH:D008607), congenital heart or renal defects (MESH:D006330), RSTS (MESH:D012415)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** c.1094A>G, c.3401A>T, c.1093_1096del, c.1942C>T, c.5028_5029dup, c.4133+2T>G, c.-49_12del, c.3044_3045del, c.4963dup, c.289C>T, c.3178A>T, c.4713_4722del

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12564014/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12564014/full.md

## References

33 references — full list in the complete paper: https://tomesphere.com/paper/PMC12564014/full.md

---
Source: https://tomesphere.com/paper/PMC12564014